Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Spero Therapeutics (SPRO) will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spero Therapeutics (SPRO) will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026. President and CEO Esther Rajavelu will speak at 9:15 AM ET at the Lotte New York Palace in New York City. Leadership will also be available for one-on-one meetings. A webcast will be accessible through Spero's Events + Presentations webpage, with a replay available for approximately 90 days following the conference.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.
| Presentation Details | |
| Date / time: | October 20, 2026, 9:15 AM ET |
| Format: | Fireside chat |
| Location: | Holmes II, Lotte New York Palace |
| Webcast Link | Here |
The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please contact your institutional representative at Chardan.
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company's lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
